Production of biological nanoparticles from bovine serum albumin as controlled release carrier for curcumin delivery

This study described a curcumin (CUR) loaded bovine serum albumin nanoparticles (BSA@CUR NPs), which could solubilize the poorly water-soluble drug and increase the therapeutic efficacy of the drug. BSA@CUR NPs were synthesized by a simple coacervation procedure. The resultant BSA@CUR NPs showed a s...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of biological macromolecules Vol. 115; pp. 83 - 89
Main Authors Salehiabar, Marziyeh, Nosrati, Hamed, Javani, Elham, Aliakbarzadeh, Faezeh, Kheiri Manjili, Hamidreza, Davaran, Soodabeh, Danafar, Hossein
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.08.2018
Subjects
Albumin
BSA
Controlled release
Curcumin
Drug delivery
Protein
Albumin
BSA
Drug delivery
Curcumin
Controlled release
Protein
Online AccessGet full text

Cover

More Information
Summary:This study described a curcumin (CUR) loaded bovine serum albumin nanoparticles (BSA@CUR NPs), which could solubilize the poorly water-soluble drug and increase the therapeutic efficacy of the drug. BSA@CUR NPs were synthesized by a simple coacervation procedure. The resultant BSA@CUR NPs showed a spherical shape, with a diameter of 92.59±16.75nm (mean ± SD) nm and a ζ-potential of – 9.19mV. The in vitro drug release study of CUR showed a sustained and controlled release pattern. Cellular toxicity of BSA NPs was also investigated on HFF2 cell lines. Additionally, a hemolysis test of as prepared NPs were performed for investigation of hemocompatibility. Hemolysis assay and cytotoxicity study results on HFF-2 cell line show that as prepared BSA NPs are biocompatible. The in vitro anticancer activity of the BSA@CUR NPs were performed by MTT assay on MCF-7 cancer cells. These results suggest that BSA@CUR NPs are a new drug delivery system for cancer therapy.
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2018.04.043